Liquidia Corp Files 8-K Report

TL;DR

Liquidia Corp filed a routine 8-K, mostly financial exhibits. No major news.

AI Summary

On April 1, 2024, Liquidia Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided excerpt. The company is incorporated in Delaware and its principal executive offices are located in Morrisville, North Carolina.

Why It Matters

This filing indicates routine corporate reporting, providing transparency to investors about the company's financial status and adherence to regulatory requirements.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for financial statements and exhibits, indicating no immediate or significant new risks.

Key Players & Entities

• Liquidia Corporation (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Morrisville, North Carolina (location) — Principal executive offices
• April 1, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• tm2410292d1_8k.htm (8-K) — 27KB
• tm2410292d1_ex99-1.htm (EX-99.1) — 16KB
• 0001104659-24-041462.txt ( ) — 218KB
• lqda-20240401.xsd (EX-101.SCH) — 3KB
• lqda-20240401_lab.xml (EX-101.LAB) — 33KB
• lqda-20240401_pre.xml (EX-101.PRE) — 22KB
• tm2410292d1_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. As previously disclosed, in December 2023, Liquidia Corporation, a Delaware Corporation (the "Company"), filed a request for Judge Andrews of the U.S. District Court for the District of Delaware (the "Delaware District Court") to set aside the injunction that was instituted in August 2022 tied to litigation filed by United Therapeutics Corporation ("United Therapeutics") alleging patent infringement of U.S. Patent No. 10,716,793 in Case No. 1:20-cv-00755-RGA (the "Original Hatch-Waxman Litigation"). On April 1, 2024, the Company issued a press release announcing that, on March 28, 2024, Judge Andrews set aside the injunction issued in the Original Hatch-Waxman Litigation. As a result, the U.S. Food and Drug Administration (the "FDA") is no longer enjoined from issuing final approval of the Company's New Drug Application ("NDA") for YUTREPIA (treprostinil) inhalation powder ("YUTREPIA"). United Therapeutics has filed a notice of appeal with respect to Judge Andrews' decision to set aside the injunction. In addition, United Therapeutics has filed two separate lawsuits in which it is seeking to obtain new injunctions to prevent the launch of YUTREPIA for the treatment of pulmonary hypertension associated with interstitial lung disease ("PH-ILD"). In the first action, United Therapeutics filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (the "D.C. District Court") (Case No. 24-484), and a motion for a temporary restraining order and preliminary injunction, seeking to prevent the FDA from granting effective approval to the Company's amended NDA from July 2023 which added the indication to treat PH-ILD. After a hearing was held on March 29, 2024, Judge Bates, who is presiding over this lawsuit in the D.C. District Court, denied United Therapeutics' motion. The D.C. District Court has scheduled a status conference for April 2, 2024, to establish a process for United Therapeutics' claims to be reevaluated aft

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 99.1 Press Release of Liquidia Corporation, dated April 1, 2024. 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. April 1, 2024 Liquidia Corporation By: /s/ Michael Kaseta Name: Michael Kaseta Title: Chief Financial Officer and Chief Operating Officer